Fungus that may have caused 'King Tut's curse' shows promise in treating cancer
When you buy through links on our articles, Future and its syndication partners may earn a commission.
A toxic fungus, once thought to have caused fatal lung infections in tomb explorers, may hold the key to powerful new cancer treatments, new research suggests.
Within months of the discovery of the tomb of King Tutankhamun in 1922, the earl who had financed the excavation and visited the "wonderful" burial site died, leading many to believe the mummy had cursed those who entered the tomb. In the 1970s, 10 of the 12 archaeologists excavating the 15th-century crypt of King Casimir IV in Poland also met a similar fate.
Analysis of Casimir's tomb revealed the presence of a fungus called Aspergillus flavus, the toxins of which are known to cause a deadly lung infection.
Now, the same fungus has shown promise as a treatment for leukaemia, according to a new study published in Nature Chemical Biology. The researcher team identified and engineered a class of molecules within the fungus, called asperigimycins, that kill leukemia cells in a laboratory setting.
"This is nature's irony at its finest," study senior author Sherry Gao, a professor of chemical and biomolecular engineering at the University of Pennsylvania, said in a statement. "The same fungus once feared for bringing death may now help save lives."
Aspergillus flavus produces spores that are able to lie dormant for centuries — including inside sealed tombs. When disturbed, the fungus can cause deadly respiratory infections, particularly in people with weakened immune systems.
Related: College student discovers psychedelic fungus that eluded LSD inventor
In their new study, the scientists examined the unique chemical compounds produced by the fungus and discovered a class of natural compounds called RiPPs (ribosomally synthesized and post-translationally modified peptides). These molecules are difficult to isolate and rarely seen in fungi, but they hold therapeutic promise due to their complex structures and bioactivity. This means they have intricate, unique shapes that can interact with biological systems in powerful ways, such as killing cancer cells.
"We found four novel asperigimycins with an unusual interlocking ring structure," lead author Qiuyue Nie, a researcher in chemical and biomolecular engineering at the University of Pennsylvania, said in the statement. "Two of them had strong anti-leukemia properties even without modification."
To enhance the drugs' effectiveness, the researchers attached lipid molecules similar to those found in royal jelly, the nutrient-rich substance that sustains queen bees. This enabled the drugs to enter cancer cells more efficiently, because lipids help drugs cross cellular membranes, which are made largely of fats themselves.
Further analysis revealed how a gene called SLC46A3 acts as a kind of molecular gateway, helping the drug escape cellular compartments and target leukemia cells directly. This discovery could aid in the delivery of other promising but hard-to-administer drugs in the future.
RELATED STORIES
—'The most critically harmful fungi to humans': How the rise of C. auris was inevitable
—Mysterious artifacts from King Tut's tomb might have been used in 'awakening Osiris' ritual
—Single gene may help explain the plague's persistence throughout human history
Unlike broad-spectrum chemotherapy agents that can damage healthy cells, asperigimycins appear to specifically disrupt leukemia cell division without affecting healthy tissues. Early tests also suggest the compounds have minimal effects on breast, liver, and lung cancer cells. According to the researchers, this selectivity is important for minimizing unwanted side effects.
In addition to asperigimycins, the team believe similar life-saving compounds may be hidden in other fungal species.
The team are planning to test asperigimycins in animal models, with the eventual goal of launching human clinical trials. And by scanning fungal genomes and exploring more strains of Aspergillus, they hope to unlock new treatments.
"The ancient world is still offering us tools for modern medicine," said Gao. "The tombs were feared for their curses, but they may become a wellspring of cures."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Deadly fungus tied to a pharaoh's tomb may help fight cancer
When you buy through links on our articles, Future and its syndication partners may earn a commission. A fatal fungus once thought to be a curse could potentially help fight disease. Scientists discovered molecules in a fungus linked to Tutankhamun's tomb that stop the proliferation of cancer cells and are as effective as currently used treatments. Fungi may hold a treasure trove of medical breakthroughs just waiting to be unearthed. The "pharaoh's curse" fungus, Aspergillus flavus, can be used to fight leukemia, according to a study published in the journal Nature Chemical Biology. The fungus is called "pharaoh's curse" because it is "linked to the deaths of several archeologists who opened ancient tombs around the world, including the famous discovery of the Tomb of Tutankhamun in the 1920s," said Popular Mechanics. At the time, many believed the deaths to be the result of an ancient curse rather than fungal inhalation. Aspergillus flavus is known as a "microbial villain," said Popular Science. It is "one of the most frequently isolated mold species in both agriculture and medicine," and is "commonly found in soil and can infect a broad range of important agricultural crops." Exposure to the fungus can lead to lung infections, especially in those who are immunocompromised. Despite its deadly reputation, the fungus contains a class of peptides that can fight cancer when modified. Researchers were able to isolate four molecules from A. flavus, which they named "asperigimycins." The molecules were capable of forming a unique structure of interlocking rings. "Even without genetic modifications, the asperigimycins demonstrated medical potential when mixed together with human cancer cells," said Popular Science. "Two out of the four variants had potent effects against leukemia cells." When fatty molecules called lipids were added to the mix, the asperigimycins were as effective as the FDA-approved drugs used to treat the cancer. There also seem to be no apparent side effects from A. flavus. Asperigimycins are part of a class of molecules called ribosomally synthesized and post-translationally modified peptides, or RiPPs. A number of them have been found in bacteria, but they are "rare in fungi and notoriously hard to study," said Wired. This is "mainly because no one was looking closely until now." However, "even though only a few have been found, almost all of them have strong bioactivity," Qiuyue Nie, a postdoctoral fellow at the University of Pennsylvania and an author of the study, said in a statement. "This is an unexplored region with tremendous potential." Fungi have long been a source of medicine, perhaps most famously the antibiotic penicillin. This research implies there is more where that came from. "Nature has given us this incredible pharmacy," Sherry Gao, an associate professor at UPenn and the senior author of the study, said in the statement. "It's up to us to uncover its secrets. As engineers, we're excited to keep exploring, learning from nature and using that knowledge to design better solutions." The next step in the process will be to test the newly discovered treatment on animals and then eventually on humans. It will likely still be many years before the treatments can be widely used on people.
Forbes
a day ago
- Forbes
The Prototype: King Tut's Curse Might Kill Leukemia
In this week's edition of The Prototype, we look at cancer-killing fungi, robots that perform surgery on your eyeballs, genetically modified bacteria that turn plastic into Tylenol and more. You can sign up to get The Prototype in your inbox here . Getty Images W hen I was a kid, I was obsessed with King Tut's tomb–and the legends of the curse put upon the team that discovered it. Of course, the stories were false and many of the tomb's discoverers lived long lives after finding it. But King Tut may have claimed at least one victim, Lord Carnarvon, thanks to a toxic fungus called aspergillus that had lain dormant for centuries. Now that 'curse' may be hitting a different target–leukemia. A new study published this week found that chemical compounds in aspergillus, when purified, show anti-cancer properties. And if a fatty molecule is added to the purified fungus the resulting compound demonstrates cancer-fighting activity similar to that of drugs currently used to treat leukemia. Next up, the scientists plan to take the most promising chemical candidates and test them on cancer in animals. If successful there, the chemicals could one day be used to treat human cancer patients. Forsight Robotics C ataract surgery is one of the world's most common medical procedures, with more than 4 million of them done each year in the United States alone, but there simply aren't enough doctors available to meet the demand for everyone who needs the surgery. An Israeli startup is betting that robots can someday easy that demand by doing the procedure better and cheaper than human doctors. ForSight Robotics on Tuesday said it had raised $125 million led by Eclipse Ventures to expand Oryom, its robotic surgery platform for cataracts and other eye diseases . The funding is the second-largest Series B investment in a surgical robotics startup, and brings ForSight's total investment to $195 million. The new money values the company at an estimated $500 million—a substantial increase since it last raised funds in 2022 at a $162 million valuation, according to VC database PitchBook. Additional investors include Fred Moll, the cofounder of Intuitive Surgical and pioneer of robotic surgery, who has joined the company's strategic advisory board. ForSight has been testing its robot on pig eyes, and plans to complete its first full robotic surgery on a human patient later this year. It's targeting the U.S. market and is in early conversations with the FDA. While ForSight's robots would be the first for cataracts, robotic surgery has become increasingly commonplace since $185 billion (market cap) Intuitive Surgical received FDA approval for its Da Vinci robots, which enable precision procedures, 25 years ago. 'At first people were intimidated by robotics' advancement,' Dr. Joseph Nathan, ForSight's cofounder, president and chief medical officer, told Forbes. 'Now they are seeing robotics as the thing that will get them the best outcomes.' Read the whole story at Forbes DISCOVERY OF THE WEEK: TURNING PLASTIC INTO PAINKILLERS Researchers at the University of Edinburgh have genetically engineered a bacteria that can take waste plastic and turn it into an ingredient used in acetaminophen (aka Tylenol). To make this work, they chemically broke down PET, a common plastic used in food packaging, into a simpler molecule and added it to a cell culture. The bacteria then produced special enzymes that interacted with the plastic molecule, transforming it into the painkiller ingredient. The researchers found that over 90% of the plastic was transformed into the drug, and the process used less energy than the conventional way to produce it from crude oil. The team's next step is to develop a way to scale the process to provide a more sustainable way to manufacture acetaminophen, with the backing of pharmaceutical companies like AstraZeneca. FINAL FRONTIER: FIRST PHOTOS FROM VERA RUBIN OBSERVATORY The Vera C. Rubin observatory, a giant telescope built in the mountains of Chile, released its first images of space this week. The observatory used a $168 million car-size digital camera tag of –paired with a unique three-mirror telescope to not only capture the unprecedentedly high-resolution images of a cluster of galaxies in the constellation Virgo, but also monitor changes in that part of the sky thanks to its ability to record time-lapsed videos. WHAT ELSE I WROTE THIS WEEK In my other newsletter, InnovationRx, Amy Feldman and I looked at health insurance companies promising to improve the prior authorization process (again), how Bell Labs plans to commercialize its massive IP portfolio, American attitudes towards vaccinating kids, and more. SCIENCE AND TECH TIDBITS NASA's James Webb Space Telescope has discovered its first planet outside the solar system. About the size of Saturn, the new world is circling a red dwarf star about 111 light-years away. Self-driving taxi company Waymo has begun operating in Atlanta, marking the fifth major U.S. city its services are available in. The Trump administration has terminated millions of dollars of government subscriptions to the Springer Nature group, which publishes major scientific journals such as Nature . After months of delays, SpaceX launched its fourth mission with Axiom Space, sending four astronauts to the International Space Station where they will conduct a wide variety of scientific experiments for Axiom's customers. PRO SCIENCE TIP: MAKE YOUR BUSINESS MORE PROFITABLE WITH AN IPO A new study of the brains of mice suggests that one of the best ways to learn a new task is to devote time to not learning it. The researchers found that mice learned more quickly when they were allowed to explore new environments without focusing on any particular task. Evidently areas of the brain developed during unstructured activities can help expedite the completion of specific tasks. If that holds true in humans, it may be a good idea to stay productive by making sure you take the time to be unproductive. WHAT'S ENTERTAINING ME THIS WEEK I recently finished the novel The Book Censor's Library by Bothayna Al-Essa. It's set in a dystopian future where censorship is the norm. The story follows the titular censor, who in his ambition to be good in his new job finds himself falling in love with reading. That leads him to a resistance movement, where he struggles to protect both books and his own daughter, who displays far more imagination than society will allow. MORE FROM FORBES Forbes Elon Musk Has Fired One Of His Top Tesla Lieutenants By Alan Ohnsman Forbes Why The U.S. Should Copy Canada To Fix Its Broken Air Traffic Control System By Jeremy Bogaisky Forbes The 36 Colleges Most At Risk From Pell Grant Cuts By Fiona Riley
Associated Press
2 days ago
- Associated Press
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Hummingbird Bioscience Media Contact: Crystal Ho [email protected] [email protected] +65 6979 5580 Hummingbird Bioscience Investor Contact: [email protected]
